5 results about "Bronchiectasis" patented technology

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The application discloses application of lactosylceramide in regulating inflammation related to bronchiectasis Pseudomonas aeruginosa infection. The application discloses, for the first time, the role of LacCer in amplification of inflammation related to bronchiectasis infection, proposes a new infection control mechanism from the perspective of metabolic regulation, and indicates that LacCer participates in regulation of inflammation by regulating the NLRP3 inflammasome related pathway, thereby providing a direction for targeted intervention. On this basis, the application further proves, through in-vivo experiments, that inhibition of LacCer synthesis can intervene in inflammation and lung injury related to bronchiectasis infection, thereby providing a new potential treatment strategy for control of inflammation related to bronchiectasis infection.

Nitrile derivative compounds represented by Chemical Formula I, stereoisomers thereof, deuteration products, cocrystals, solvates, or pharmaceutically acceptable salts are provided, wherein each group is defined as in the detailed description. The compounds have dipeptidyl peptidase 1 inhibitory activity and can be used to manufacture drugs for treating obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, chronic obstructive pulmonary disease and other diseases. [Chemical Formula I]

The invention therefore provides methods of treating a respiratory disease characterized by mucus hyper-secretion comprising administering to a human patient in need of such treatment a gamma secretase inhibitor (GSI), wherein the administration of a GSI is effective in reducing mucus in such patient's lungs or inhibiting mucus accumulation in said patient's lungs. In some embodiments, the methods of the invention are effective in treating a respiratory disease selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, primary ciliary dyskinesis, chronic bronchitis, asthma, idiopathic and secondary bronchiectasis, bronchiolitis obliterans, idiopathic pulmonary fibrosis, respiratory infection and mucus accumulation in response to infection. Methods of the invention further include methods of treating cystic fibrosis wherein a GSI is administered to a patient being administered or in need of a CFTR modulator, wherein the mucus in such patient's lungs is reduced or mucus accumulation in such patient's lungs is inhibited.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.